Alexander Perl Md On The Toxicity In The Phase 3 Study Evaluating Cpx 351 Vyxeos Obroncology Mp3 & Mp4 Download

0:32

alexander perl, md on treatment based on the phase iii study evaluating cpx-351 (vyxeos) versus 7 3

1:23

alexander perl, md discusses cpx-351 (vyxeos) mechanism of action and why it is a promising agent

0:55

aref al-kali, md, discusses the toxicity of the cpx-351 (vyxeos) in the phase iii study

1:21

mark levis, md, on the mechanism of action for cpx-351 (vyxeos) and why is it promising in aml

0:41

aref al-kali, md, discusses the impact of the cpx-351 (vyxeos) phase iii results on treatment

0:58

eunice s. wang, md, discusses the toxicity of the cpx-351 (vyxeos) in a phase iii study

1:18

alexander perl, md, on flt3 inhibitors in development and importance of hitting the flt3 target

1:25

alexander perl, md, on importance of flt3 and provides his perspective on inhibitor differences

2:10

alexander perl, md, on prognosis, diagnosis and treatment strategies for aml

1:17

alexander perl, md, on the role of immunotherapy in treating hematological malignancies

0:35

aref al-kali, md, discusses cpx-351 (vyxeos) phase iii results in subsets

0:58

alexander perl, md, discusses the importance of sustained inhibition when selecting a flt3 inhibitor

0:53

alexander perl, md, discusses the quantum first study and potential implications

1:01

alexander perl, md, on how the beat aml master trial will change the way aml patients are treated

1:14

alexander perl, md, discusses the potential impact of potency when selecting a flt3 inhibitor

1:22

alexander perl, md, on aml trial results presented at this year’s ash meeting

1:59

alexander perl, md, discusses treatment options for aml patients

0:59

alexander perl, md, discusses how molecular testing can facilitate decision making in aml patients

9:39

alexander perl, md, on the toxicity in the phase 3 study evaluating cpx-351 (vyxeos)

Download video MP4

Download video MP3

Similar videos

alexander perl, md on treatment based on the phase iii study evaluating cpx-351 (vyxeos) versus 7 3

alexander perl, md discusses cpx-351 (vyxeos) mechanism of action and why it is a promising agent

aref al-kali, md, discusses the toxicity of the cpx-351 (vyxeos) in the phase iii study

mark levis, md, on the mechanism of action for cpx-351 (vyxeos) and why is it promising in aml

aref al-kali, md, discusses the impact of the cpx-351 (vyxeos) phase iii results on treatment

eunice s. wang, md, discusses the toxicity of the cpx-351 (vyxeos) in a phase iii study

alexander perl, md, on flt3 inhibitors in development and importance of hitting the flt3 target

alexander perl, md, on importance of flt3 and provides his perspective on inhibitor differences

alexander perl, md, on prognosis, diagnosis and treatment strategies for aml

alexander perl, md, on the role of immunotherapy in treating hematological malignancies

aref al-kali, md, discusses cpx-351 (vyxeos) phase iii results in subsets

alexander perl, md, discusses the importance of sustained inhibition when selecting a flt3 inhibitor

alexander perl, md, discusses the quantum first study and potential implications

alexander perl, md, on how the beat aml master trial will change the way aml patients are treated

alexander perl, md, discusses the potential impact of potency when selecting a flt3 inhibitor

alexander perl, md, on aml trial results presented at this year’s ash meeting

alexander perl, md, discusses treatment options for aml patients

alexander perl, md, discusses how molecular testing can facilitate decision making in aml patients

alexander perl, md: the new flt3 inhibitor gilteritinib is “well-tolerated” in aml